Summary
Five new antagonists of Substance P were designed and synthesized toward increasing potency and safety. One of them was more effective than Spantide II, which was the basis for the design. It was named Spantide III and has the structure: D-NicLys,Pro,Pal,Pro,D-Cl2Phe,Asn,D-Trp,Phe,D-Pal,Leu, NleNH2.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fewtrell CMS, Foreman JC, Jordan CC, Dehme P, Renner H, Stewart JM (1982) The effects of substance P on histamine and 5-hydroxytryptamine release in the rat. J Physiol (Lond) 330: 393–411
Folkers K, Hakanson R, Hong J, Xu J-C, Leander S (1984) Biological evaluation of substance P antagonists. Br J Pharmacol 83: 449–456
Folkers K, Rosell S, Chu J-Y, Lu Y-A, Tang PF-L, Ljungqvist A (1986) Design and synthesis of antagonists of substance P. Acta Chem Scand 1340: 295–302
Folkers K, Feng D-M, Asano N, Hakanson R, Weisenfeld-Hallin Z, Leander S (1990) Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity. Proc Natl Acad Sci USA 87: 4833–4835
Hakanson R, Leander S, Asano N, Feng D-M, Folkers K (1990) Spantide II, a novel tachykinin antagonist having high potency and low histamine releasing effect. Reg Pep 31: 75–82
Hakanson R, Wang Z-Y, Folkers K (1991) Comparison of Spantide II and CP-96,345 for blockade of tachykinin evoked contractions of smooth muscle. Biomod Biophys Res Comm 178: 297–301
Ljungqvist A, Feng D-M, Tang P-FL, Kubata M, Okamoto K, Zhang Y, Bowers CY, Hook W, Folkers K (1985) Design, synthesis, and bioassay of antagonists of LHRH which have high antiovulatory activity of release negligible histamine. Biochem Biophys Res Comm 148: 849–856
Ljungqvist A, Chu J-Y, Tang P-FL, Bender W, Hakanson S, Leander S, Rosell S, Folkers K (1989) Increased potency of anagonists of substance P having asparagine in position 6. Reg Pept 24: 283–291
Maggi CA, Patacchini R, Feng D-M, Folkers K (1991) Activity of Spantide I and II at various tachykinin receptors and NK-2 tachykinin receptor subtypes. Eur J Pharmacol 199: 127–129
Mizrahi J, Escher E, Caranikas S, D'Orleans-Juste P, Regoli D (1982) Substance P antagonist active in vitro and in vivo. Eur J Pharmacol 82: 101–105
Post C, Paulsson I (1986) Antinociceptive and neurotoxic actions of substance P analogs in the rats spinal cord after intrathecal administration. Neuroscience Lett 57: 159–164
Regoli D, Escher E, Mizrahi J (1984) Substance P: structure-activity studies and the development of antagonists. Pharmacology 28: 301–306
Regoli D, Mizrahi J, D'Orleans-Juste P, Dion S, Drapeau C, Escher E (1985) Substance P antagonists showing some selectivity for different receptor types. Eur Pharmacol 109: 121–125
Wang Z-Y, Feng D-M, Folkers K, Hakanson R (1992) Pharmacological evaluation of Spantide II and the new Spantide III. Eur J Phamacol (in press)
Watling K (1992) Nonpeptide antagonists herald new era in tachykinin research. Trends Pharmacol Sci 13: 266–269
Weisenfeld-Hallin Z, Xu X-J, Kristensson K, Hakanson R, Feng D-M, Folkers K (1990) Antinociceptive and substance P antagonistic effects of intrathecally injected Spantide II in rat: no signs of motor impairment or neurotoxicity. Reg Pept 29: 1–11
Yamaguchi I, Rackur G, Leban JJ, Bjorkroth U, Rosell S, Folkers K (1978) Synthesis and biological activity of analogs of substance P, modified for conformational information by D-amino acids. Acta Chem Scand B33: 63–68
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Folkers, K., Hakanson, R., Feng, D.M. et al. Spantide III, a superior tachykinin antagonist with high potency and negligible neurotoxicity. Amino Acids 5, 233–238 (1993). https://doi.org/10.1007/BF00805985
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00805985